PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
Name:
36352028.pdf
Size:
964.1Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Propper, D. J.Gao, F.
Saunders, Mark P
Sarker, D.
Hartley, J. A.
Spanswick, V. J.
Lowe, H. L.
Hackett, L. D.
Ng, T. T.
Barber, P. R.
Weitsman, G. E.
Pearce, S.
White, L.
Lopes, A.
Forsyth, S.
Hochhauser, D.
Affiliation
Barts Cancer Institute, Queen Mary, University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UKIssue Date
2022
Metadata
Show full item recordAbstract
Background: Epidermal growth factor receptor (EGFR) is a therapeutic target to which HER2/HER3 activation may contribute resistance. This Phase I/II study examined the toxicity and efficacy of high-dose pulsed AZD8931, an EGFR/HER2/HER3 inhibitor, combined with chemotherapy, in metastatic colorectal cancer (CRC). Methods: Treatment-naive patients received 4-day pulses of AZD8931 with irinotecan/5-FU (FOLFIRI) in a Phase I/II single-arm trial. Primary endpoint for Phase I was dose limiting toxicity (DLT); for Phase II best overall response. Samples were analysed for pharmacokinetics, EGFR dimers in circulating exosomes and Comet assay quantitating DNA damage. Results: Eighteen patients received FOLFIRI and AZD8931. At 160 mg bd, 1 patient experienced G3 DLT; 160 mg bd was used for cohort expansion. No grade 5 adverse events (AE) reported. Seven (39%) and 1 (6%) patients experienced grade 3 and grade 4 AEs, respectively. Of 12 patients receiving 160 mg bd, best overall response rate was 25%, median PFS and OS were 8.7 and 21.2 months, respectively. A reduction in circulating HER2/3 dimer in the two responding patients after 12 weeks treatment was observed. Conclusions: The combination of pulsed high-dose AZD8931 with FOLFIRI has acceptable toxicity. Further studies of TKI sequencing may establish a role for pulsed use of such agents rather than continuous exposure.Citation
Propper DJ, Gao F, Saunders MP, Sarker D, Hartley JA, Spanswick VJ, et al. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer. British journal of cancer. 2022 Nov 9. PubMed PMID: 36352028. Epub 2022/11/10. eng.Journal
British Journal of CancerDOI
10.1038/s41416-022-02015-xPubMed ID
36352028Additional Links
https://dx.doi.org/10.1038/s41416-022-02015-xType
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41416-022-02015-x